United States childhood vaccine schedule: 13 vaccines by age
For babies (first year): Hepatitis B, DTaP / Tdap, Polio (IPV), Hib, Pneumococcal (PCV), Rotavirus, MMR, Varicella (chickenpox), Hepatitis A, Influenza (flu), COVID-19. Click a vaccine for its United States-specific page and its schedule in every other country.
| Vaccine | Status | Doses & recommended age |
|---|---|---|
| Hepatitis B · side effects & data | Universal | Dose 1 — Birth Dose 2 — 1-2 months Dose 3 — 6-18 months |
| DTaP / Tdap · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months Dose 4 — 15-18 months Dose 5 — 4-6 years |
| Polio (IPV) · side effects & data | Universal | Dose 1 — 2 months (IPV) Dose 2 — 4 months (IPV) Dose 3 — 6-18 months (IPV) Dose 4 — 4-6 years (IPV) |
| Hib · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months Dose 4 — 12-15 months |
| Pneumococcal (PCV) · side effects & data | Universal | Dose 1 — 2 months (PCV15 or PCV20) Dose 2 — 4 months (PCV15 or PCV20) Dose 3 — 6 months (PCV15 or PCV20) Dose 4 — 12-15 months (PCV15 or PCV20) |
| Rotavirus · side effects & data | Universal | Dose 1 — 2 months (RV5 or RV1) Dose 2 — 4 months (RV5 or RV1) Dose 3 — 6 months (RV5 or RV1) |
| MMR · side effects & data | Universal | Dose 1 — 12-15 months Dose 2 — 4-6 years |
| Varicella (chickenpox) · side effects & data | Universal | Dose 1 — 12-15 months Dose 2 — 4-6 years |
| Hepatitis A · side effects & data | Universal | Dose 1 — 12-23 months Dose 2 — 6-18 months after dose 1 |
| Meningococcal · side effects & data | Universal | Dose 1 — 11-12 years (MenACWY) Booster — 16 years (MenACWY) |
| HPV · side effects & data | Universal | Dose 1 — 11-12 years Dose 2 — 6-12 months after dose 1 |
| Influenza (flu) · side effects & data | Universal | Annual — 6 months and older, every season |
| COVID-19 · side effects & data | Selective / risk-based | Current dose — 6 months and older |
United States vaccine schedule vs. the United States
The U.S. schedule has 13 routine vaccines; COVID-19 are the ones fewest other countries share.
How many of the other 30 countries in this dataset also include each U.S. routine vaccine:
| U.S. vaccine | U.S. first dose | Elsewhere |
|---|---|---|
| Hepatitis B | Birth | 29 of 30 other countries also give it routinely |
| DTaP / Tdap | 2 months | 30 of 30 other countries also give it routinely |
| Polio (IPV) | 2 months | 30 of 30 other countries also give it routinely |
| Hib | 2 months | 30 of 30 other countries also give it routinely |
| Pneumococcal (PCV) | 2 months | 28 of 30 other countries also give it routinely |
| Rotavirus | 2 months | 25 of 30 other countries also give it routinely |
| MMR | 12-15 months | 30 of 30 other countries also give it routinely |
| Varicella (chickenpox) | 12-15 months | 16 of 30 other countries also give it routinely |
| Hepatitis A | 12-23 months | 8 of 30 other countries also give it routinely |
| Meningococcal | 11-12 years | 11 of 30 other countries also give it routinely |
| HPV | 11-12 years | 27 of 30 other countries also give it routinely |
| Influenza (flu) | 6 months and older, every season | 25 of 30 other countries also give it routinely |
| COVID-19 | 6 months and older | 0 of 30 other countries also give it routinely |
Why United States's schedule looks the way it does
Schedules differ mostly because disease burden and health-system conditions differ. WHO/UNICEF estimates of how many children actually receive each vaccine, and the diseases' reported incidence, explain most of the choices below.
- Tuberculosis: 3.2 new cases per 100,000 people per year (2024). BCG is not in the national schedule. BCG mainly protects young children from severe TB (meningitis, miliary TB), so countries with high TB incidence give it at birth and low-incidence countries reserve it for risk groups.
- Measles: 0.4 reported cases per million people (2023). Two-dose coverage is 95%; sustained elimination needs roughly 95% coverage with both doses, which is why schedules add or move the second dose when coverage or outbreaks change.
- Hepatitis B birth dose: 75% coverage. A birth dose matters most where mothers commonly carry hepatitis B, because infection at birth becomes chronic in most infants; countries with low carriage and universal prenatal screening often start hepatitis B vaccination later or target only exposed newborns.
Coverage: share of children who received each vaccine (WHO/UNICEF estimates)
| Vaccine | United States |
|---|---|
| BCG (TB) | not reported |
| DTP dose 1 | 98% (2025) |
| DTP dose 3 | 94% (2025) |
| Measles dose 1 | 92% (2025) |
| Measles dose 2 | 95% (2025) |
| Polio (IPV series) | 93% (2025) |
| Hep B birth dose | 75% (2025) |
| Hep B dose 3 | 93% (2025) |
| Hib dose 3 | 92% (2025) |
| Pneumococcal (PCV) | 84% (2025) |
| Rotavirus (complete) | 77% (2025) |
| HPV dose 1, girls | 73% (2025) |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and WHO reported incidence, via the WHO Immunization Data portal; TB incidence from the WHO Global Health Observatory (indicator MDG_0000000020). Retrieved 2026-10-09. "Not reported" usually means the vaccine is not in the universal schedule. Polio is the completed inactivated-polio series (IPVC).